Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: Pilot animal and human studies

R. L. Wahl, J. Harney, Gary Hutchins, H. B. Grossman

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The feasibility of imaging renal cancers with 2-deoxy-2-[18F]-fluoro-D-glucose (FDG) and whole-body positron emission tomographic scanning was assessed in nude mice with human renal adenocarcinoma xenografts and then in 5 patients with primary renal cancer (4 adenocarcinomas and 1 transitional cell carcinoma). In nude mouse biodistribution studies tumor FDG uptake was maximal at 0.33 to 2 hours but tumor-to-blood ratios increased continuously to 7.8/1. by 4 hours after intravenous FDG injection. In all 5 patients primary and metastatic tumors were imaged within 1 hour by FDG positron emission tomography following intravenous injection of the FDG. By contrast, an hepatic hemangioma did not accumulate FDG. In summary, FDG metabolic and anatomical imaging of primary and metastatic renal cancer is feasible and in these pilot studies appears to be a promising imaging methodology that may be further enhanced by delayed imaging times. Additional study in a larger number of patients is essential to define better the accuracy and potential clinical use of this method.

Original languageEnglish (US)
Pages (from-to)1470-1474
Number of pages5
JournalJournal of Urology
Volume146
Issue number6
StatePublished - 1991
Externally publishedYes

Fingerprint

Kidney Neoplasms
Fluorodeoxyglucose F18
Positron-Emission Tomography
Nude Mice
Intravenous Injections
Neoplasms
Transitional Cell Carcinoma
Hemangioma
Renal Cell Carcinoma
Heterografts
Adenocarcinoma
Electrons
Liver

Keywords

  • Adenocarcinoma
  • Carcinoma, transitional cell
  • Kidney neoplasms
  • Positrons
  • Tomography, emission-computed

ASJC Scopus subject areas

  • Urology

Cite this

Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose : Pilot animal and human studies. / Wahl, R. L.; Harney, J.; Hutchins, Gary; Grossman, H. B.

In: Journal of Urology, Vol. 146, No. 6, 1991, p. 1470-1474.

Research output: Contribution to journalArticle

@article{bd587113fd984f9c81bce16e2e4ab3a3,
title = "Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose: Pilot animal and human studies",
abstract = "The feasibility of imaging renal cancers with 2-deoxy-2-[18F]-fluoro-D-glucose (FDG) and whole-body positron emission tomographic scanning was assessed in nude mice with human renal adenocarcinoma xenografts and then in 5 patients with primary renal cancer (4 adenocarcinomas and 1 transitional cell carcinoma). In nude mouse biodistribution studies tumor FDG uptake was maximal at 0.33 to 2 hours but tumor-to-blood ratios increased continuously to 7.8/1. by 4 hours after intravenous FDG injection. In all 5 patients primary and metastatic tumors were imaged within 1 hour by FDG positron emission tomography following intravenous injection of the FDG. By contrast, an hepatic hemangioma did not accumulate FDG. In summary, FDG metabolic and anatomical imaging of primary and metastatic renal cancer is feasible and in these pilot studies appears to be a promising imaging methodology that may be further enhanced by delayed imaging times. Additional study in a larger number of patients is essential to define better the accuracy and potential clinical use of this method.",
keywords = "Adenocarcinoma, Carcinoma, transitional cell, Kidney neoplasms, Positrons, Tomography, emission-computed",
author = "Wahl, {R. L.} and J. Harney and Gary Hutchins and Grossman, {H. B.}",
year = "1991",
language = "English (US)",
volume = "146",
pages = "1470--1474",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose

T2 - Pilot animal and human studies

AU - Wahl, R. L.

AU - Harney, J.

AU - Hutchins, Gary

AU - Grossman, H. B.

PY - 1991

Y1 - 1991

N2 - The feasibility of imaging renal cancers with 2-deoxy-2-[18F]-fluoro-D-glucose (FDG) and whole-body positron emission tomographic scanning was assessed in nude mice with human renal adenocarcinoma xenografts and then in 5 patients with primary renal cancer (4 adenocarcinomas and 1 transitional cell carcinoma). In nude mouse biodistribution studies tumor FDG uptake was maximal at 0.33 to 2 hours but tumor-to-blood ratios increased continuously to 7.8/1. by 4 hours after intravenous FDG injection. In all 5 patients primary and metastatic tumors were imaged within 1 hour by FDG positron emission tomography following intravenous injection of the FDG. By contrast, an hepatic hemangioma did not accumulate FDG. In summary, FDG metabolic and anatomical imaging of primary and metastatic renal cancer is feasible and in these pilot studies appears to be a promising imaging methodology that may be further enhanced by delayed imaging times. Additional study in a larger number of patients is essential to define better the accuracy and potential clinical use of this method.

AB - The feasibility of imaging renal cancers with 2-deoxy-2-[18F]-fluoro-D-glucose (FDG) and whole-body positron emission tomographic scanning was assessed in nude mice with human renal adenocarcinoma xenografts and then in 5 patients with primary renal cancer (4 adenocarcinomas and 1 transitional cell carcinoma). In nude mouse biodistribution studies tumor FDG uptake was maximal at 0.33 to 2 hours but tumor-to-blood ratios increased continuously to 7.8/1. by 4 hours after intravenous FDG injection. In all 5 patients primary and metastatic tumors were imaged within 1 hour by FDG positron emission tomography following intravenous injection of the FDG. By contrast, an hepatic hemangioma did not accumulate FDG. In summary, FDG metabolic and anatomical imaging of primary and metastatic renal cancer is feasible and in these pilot studies appears to be a promising imaging methodology that may be further enhanced by delayed imaging times. Additional study in a larger number of patients is essential to define better the accuracy and potential clinical use of this method.

KW - Adenocarcinoma

KW - Carcinoma, transitional cell

KW - Kidney neoplasms

KW - Positrons

KW - Tomography, emission-computed

UR - http://www.scopus.com/inward/record.url?scp=0026331008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026331008&partnerID=8YFLogxK

M3 - Article

C2 - 1942320

AN - SCOPUS:0026331008

VL - 146

SP - 1470

EP - 1474

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -